Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132816 | 1.00 | FAAH (0.47) | FAAHSIGMAR1CHRM2CHRM1CHRM3 | |
| SCHEMBL4149372 | 0.89 | CACNA1G (0.46) | SIGMAR1CACNA1GCHRM4 | |
| SCHEMBL5099416 | 0.89 | CACNA1G (0.46) | SIGMAR1CACNA1GCHRM4 | |
| SCHEMBL5105573 | 0.89 | CHRM3 (0.46) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5105568 | 0.89 | CHRM3 (0.46) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4143237 | 0.88 | CHRM2 (0.50) | FAAHCHRM2CHRM1CHRM3UBE2M | |
| SCHEMBL4143233 | 0.88 | CHRM2 (0.50) | FAAHCHRM2CHRM1CHRM3UBE2M | |
| SCHEMBL5099648 | 0.86 | CHRM2 (0.51) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4136009 | 0.86 | CHRM2 (0.51) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4128643 | 0.84 | CHRM3 (0.45) | FAAHCHRM2CHRM1CHRM3DCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | claimed |
| US-7446123-B2 | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-04 | — | — | US | claimed |
| US-20060287380-A1 | Azabicyclo Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-21 | — | — | US | claimed |
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-7446123-B2 | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-04 | — | — | US | disclosed |
| US-20060287380-A1 | Azabicyclo Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | ADRB2, ADRB1, ADRA2C | FAAH 1414/4885SIGMAR1 942/4885CHRM2 9/4885 |
| US-20060287380-A1 | Azabicyclo Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | FAAH 1055/4885SIGMAR1 447/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.